Romano Brothers AND Company Has $4.20 Million Stake in Bristol-Myers Squibb (NYSE:BMY)

Romano Brothers AND Company lowered its stake in Bristol-Myers Squibb (NYSE:BMY) by 1.1% in the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 81,149 shares of the biopharmaceutical company’s stock after selling 915 shares during the period. Romano Brothers AND Company’s holdings in Bristol-Myers Squibb were worth $4,199,000 at the end of the most recent quarter.

Other institutional investors have also recently bought and sold shares of the company. ESL Trust Services LLC acquired a new stake in shares of Bristol-Myers Squibb in the 1st quarter valued at $27,000. LGT Financial Advisors LLC boosted its holdings in Bristol-Myers Squibb by 42.7% in the second quarter. LGT Financial Advisors LLC now owns 759 shares of the biopharmaceutical company’s stock valued at $32,000 after acquiring an additional 227 shares during the last quarter. ORG Wealth Partners LLC acquired a new stake in Bristol-Myers Squibb in the third quarter worth about $34,000. MFA Wealth Advisors LLC bought a new stake in Bristol-Myers Squibb during the 2nd quarter worth about $39,000. Finally, Beach Investment Counsel Inc. PA acquired a new position in Bristol-Myers Squibb during the 2nd quarter valued at about $42,000. Institutional investors own 76.41% of the company’s stock.

Bristol-Myers Squibb Trading Up 0.6 %

Shares of NYSE:BMY opened at $53.06 on Thursday. The company has a debt-to-equity ratio of 2.86, a current ratio of 1.16 and a quick ratio of 1.02. The company’s 50-day moving average price is $50.63 and its two-hundred day moving average price is $46.39. The stock has a market capitalization of $107.56 billion, a PE ratio of -17.12, a price-to-earnings-growth ratio of 13.75 and a beta of 0.46. Bristol-Myers Squibb has a one year low of $39.35 and a one year high of $56.77.

Bristol-Myers Squibb (NYSE:BMY) last posted its quarterly earnings results on Friday, July 26th. The biopharmaceutical company reported $2.07 earnings per share for the quarter, topping the consensus estimate of $1.64 by $0.43. The firm had revenue of $12.20 billion for the quarter, compared to analyst estimates of $11.54 billion. Bristol-Myers Squibb had a positive return on equity of 12.51% and a negative net margin of 14.06%. The business’s quarterly revenue was up 8.7% on a year-over-year basis. During the same quarter in the previous year, the firm earned $1.75 EPS. On average, equities analysts forecast that Bristol-Myers Squibb will post 0.77 EPS for the current fiscal year.

Bristol-Myers Squibb Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Friday, November 1st. Investors of record on Friday, October 4th will be paid a $0.60 dividend. This represents a $2.40 dividend on an annualized basis and a yield of 4.52%. The ex-dividend date is Friday, October 4th. Bristol-Myers Squibb’s dividend payout ratio (DPR) is presently -77.42%.

Analyst Ratings Changes

A number of equities analysts have issued reports on BMY shares. TD Cowen raised their price objective on shares of Bristol-Myers Squibb from $53.00 to $59.00 and gave the company a “hold” rating in a research note on Monday, October 7th. StockNews.com upgraded Bristol-Myers Squibb from a “buy” rating to a “strong-buy” rating in a report on Monday, July 29th. Barclays raised their target price on Bristol-Myers Squibb from $42.00 to $43.00 and gave the stock an “underweight” rating in a report on Monday, October 7th. UBS Group increased their price target on shares of Bristol-Myers Squibb from $50.00 to $54.00 and gave the company a “neutral” rating in a research report on Wednesday, October 9th. Finally, Cantor Fitzgerald reaffirmed a “neutral” rating and issued a $50.00 target price on shares of Bristol-Myers Squibb in a research note on Friday, October 18th. Two research analysts have rated the stock with a sell rating, fourteen have given a hold rating, one has issued a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat.com, the stock presently has an average rating of “Hold” and an average target price of $53.20.

About Bristol-Myers Squibb

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation, and for the treatment of DVT/PE; Opdivo for various anti-cancer indications, including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esophageal cancer; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia.